Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. More Details
High growth potential and slightly overvalued.
Share Price & News
How has Esperion Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ESPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ESPR's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ESPR underperformed the US Biotechs industry which returned 31.5% over the past year.
Return vs Market: ESPR underperformed the US Market which returned 56.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StBullish: Analysts Just Made A Significant Upgrade To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
3 months ago | Simply Wall StNeed To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares
4 months ago | Simply Wall StEsperion Therapeutics' (NASDAQ:ESPR) Stock Price Has Reduced 58% In The Past Three Years
Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ESPR ($26.95) is trading below our estimate of fair value ($518.09)
Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ESPR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ESPR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ESPR has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ESPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ESPR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ESPR's is expected to become profitable in the next 3 years.
Revenue vs Market: ESPR's revenue (27% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ESPR's revenue (27% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time
How has Esperion Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ESPR is currently unprofitable.
Growing Profit Margin: ESPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of 11.9% per year.
Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: ESPR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Esperion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESPR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ESPR has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 15.5% each year.
What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ESPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Mayleben (59 yo)
Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
Experienced Management: ESPR's management team is considered experienced (3 years average tenure).
Experienced Board: ESPR's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Esperion Therapeutics, Inc.
- Ticker: ESPR
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$753.053m
- Shares outstanding: 27.94m
- Website: https://www.esperion.com
Number of Employees
- Esperion Therapeutics, Inc.
- 3891 Ranchero Drive
- Suite 150
- Ann Arbor
- United States
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and interna...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 22:13|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.